New cholesterol lowering drug
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
New Cholesterol-Lowering Drugs: Emerging Therapies and Mechanisms
Introduction to Cholesterol-Lowering Drugs
Cholesterol management is crucial for reducing the risk of cardiovascular diseases (CVD). While statins have been the cornerstone of cholesterol-lowering therapy, new drugs are emerging to address the limitations and side effects associated with statins. This article explores the latest advancements in cholesterol-lowering drugs, focusing on their mechanisms and clinical benefits.
Oligonucleotide Therapeutics: Small Interfering RNA (siRNA)
Inclisiran is a novel cholesterol-lowering drug that belongs to the class of small interfering RNA (siRNA) therapeutics. It works by targeting and degrading RNA before protein synthesis, specifically inhibiting the production of proprotein convertase subtilisin/kexin type 9 (PCSK9). This inhibition leads to increased recycling of low-density lipoprotein receptors (LDLR) and enhanced clearance of LDL cholesterol (LDL-C) from the bloodstream . Inclisiran is administered via injection twice a year, making it a convenient option for patients.
Berberine: A Unique Mechanism
Berberine (BBR), derived from a Chinese herb, has shown significant cholesterol-lowering effects through a mechanism distinct from statins. Clinical studies have demonstrated that BBR reduces serum cholesterol, triglycerides, and LDL-C levels. It upregulates LDLR expression in the liver through a post-transcriptional mechanism that stabilizes LDLR mRNA, independent of sterol regulatory element-binding proteins but dependent on ERK activation. This unique pathway offers an alternative for patients who are statin-intolerant or require additional lipid-lowering therapy.
PCSK9 Inhibitors: Monoclonal Antibodies
PCSK9 inhibitors are another class of drugs that have shown promise in lowering LDL-C levels. These monoclonal antibodies work by binding to PCSK9, preventing it from degrading LDL receptors on liver cells. This results in increased clearance of LDL-C from the blood. Clinical trials have demonstrated the efficacy of PCSK9 inhibitors in reducing LDL-C levels and cardiovascular events, making them a valuable option for patients who do not achieve their cholesterol goals with statins alone .
Bempedoic Acid: ATP Citrate Lyase Inhibitor
Bempedoic acid is an ATP citrate lyase inhibitor that reduces cholesterol synthesis in the liver. It is particularly beneficial for patients who are statin-intolerant. Clinical studies have shown that bempedoic acid effectively lowers LDL-C levels and has a favorable safety profile. It can be used as monotherapy or in combination with other lipid-lowering agents to achieve optimal cholesterol levels .
ANGPTL3 Inhibitors: Dual Action on LDL and Triglycerides
ANGPTL3 inhibitors target angiopoietin-like 3 protein, which plays a role in lipid metabolism. These inhibitors reduce both LDL-C and triglyceride levels, offering a dual benefit for patients with mixed dyslipidemia. Evinacumab, an ANGPTL3 monoclonal antibody, has shown significant reductions in LDL-C levels in patients with refractory hypercholesterolemia .
Antisense Oligonucleotides: Targeting Specific Lipoproteins
Antisense oligonucleotides are designed to target specific lipoproteins such as apolipoprotein C3 (apoC3) and lipoprotein(a) [Lp(a)]. These drugs work by binding to the mRNA of the target protein, preventing its translation and reducing its levels in the bloodstream. This approach has shown promise in reducing associated dyslipidemias and cardiovascular risk .
Conclusion
The landscape of cholesterol-lowering therapy is rapidly evolving with the introduction of new drugs that offer alternative mechanisms and benefits beyond traditional statins. Inclisiran, berberine, PCSK9 inhibitors, bempedoic acid, ANGPTL3 inhibitors, and antisense oligonucleotides represent significant advancements in the management of hypercholesterolemia. These emerging therapies provide new hope for patients who are statin-intolerant or require additional lipid-lowering strategies to achieve their cholesterol goals and reduce cardiovascular risk.
Sources and full results
Most relevant research papers on this topic